84 results about "Toxoplasma gondii Infections" patented technology

The invention provides protein with Toxoplasma gondii immunogenicity. The protein is cyclophilin mutant protein and consists of the amino acid sequence shown in SEQ ID 2. The invention further provides nucleic acid capable of encoding the protein with Toxoplasma gondii immunogenicity and consists of the nucleic acid sequence shown in SEQ ID 1. The invention also provides a vaccine. A Toxoplasma gondii antigen gene is subjected to double enzyme digestion, then linked to prokaryotic expression vectors such as pET28a and the like and transformed into prokaryotic expression engineering bacteria such as BL21 (DE3) and the like to be induced to be highly expressed, protein obtained after purification is soluble protein, and the specific immunogenicity of the protein is maintained. The sequence of the cyclophilin protein is optimized, so that the expression amount of the cyclophilin protein in prokaryotic Escherichia coli is remarkably increased. The vaccine can be prepared by engineering strains by adding vaccine adjuvants, unique immunogenicity of the vaccine is maintained, and the vaccine is suitable for industrial production.

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen T. gondii and their use in various diagnostic tests, vaccines, and therapeutic agents. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and / or have a known association with a disease parameter.